drug · antibody
elranatamab
Marketedupdated 3mo agoby $PFE PFIZER INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and neoplasm and 2 investigational indications.
targets
T cell surface glycoprotein CD3Tumor necrosis factor receptor superfamily member 17
all catalysts(8)
approval · 7
Aug 14, 2023
approval
$PFE26.79-0.04%
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Dec 13, 2023
approval
$PFE26.79-0.04%
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Sep 10, 2024
approval
$PFE26.79-0.04%
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Jul 8, 2025
approval
$PFE26.79-0.04%
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Jul 10, 2025
approval
$PFE26.79-0.04%
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Feb 19, 2026
approval
$PFE26.79-0.04%
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Mar 25, 2026
approval
$PFE26.79-0.04%
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Trials studying elranatamab
- phase1A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- phase2A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- phase3Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
- phase1A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- phase3MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- phase2Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
- phase1A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- phase2Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
News(3)
- CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineA Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.biopharma_dive · 3mo ago
- Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenuePfizer’s positive Phase 3 data in multiple myeloma: The company’s Elrexfio produced a “statistically significant and clinically meaningful improvement” in progression-free survival in patients with…endpoints · 3mo ago
- FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotechThrough two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multipl…biopharma_dive · 3mo ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that